Research location
Palma de Mallorca
Spain
Advertisement
Research activity in Palma de Mallorca
SpainCureCurrent currently publishes aggregate city-level research activity for this location: 313 trials and 348 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Palma de Mallorca
313 linked trials · page 1 of 7Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CMNCT07690436 · 2026-07-08 · 1 site observation
RECRUITING
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerNCT07647328 · 2026-06-15 · 1 site observation
RECRUITING
Evaluation of a Multicomponent Early Intervention for Childhood Obesity Prevention in Vulnerable FamiliesNCT07529704 · 2026-03-02 · 1 site observation
RECRUITING
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity ManagementNCT07371585 · 2026-02-18 · 1 site observation
RECRUITING
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)NCT07202546 · 2026-02-11 · 2 site observations
RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 · 2026-02-10 · 1 site observation
RECRUITING
Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibNCT07237256 · 2025-12-18 · 2 site observations
RECRUITING
NOPE37: Angiogenic Factors for Managing Term PreeclampsiaNCT07193680 · 2025-12-04 · 1 site observation
RECRUITING
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World SettingNCT07230691 · 2025-12-03 · 1 site observation
RECRUITING
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyNCT07472517 · 2025-11-07 · 1 site observation
RECRUITING
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationNCT07177339 · 2025-10-20 · 1 site observation
RECRUITING
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811 · 2025-10-02 · 1 site observation
RECRUITING
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109 · 2025-09-22 · 1 site observation
RECRUITING
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerNCT06982521 · 2025-08-26 · 1 site observation
RECRUITING
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)NCT07076407 · 2025-07-08 · 1 site observation
RECRUITING
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationNCT06959095 · 2025-06-20 · 1 site observation
RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantNCT06563895 · 2025-05-12 · 1 site observation
RECRUITING
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277 · 2025-04-10 · 1 site observation
RECRUITING
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentNCT06750289 · 2025-03-28 · 1 site observation
RECRUITING
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerNCT06989112 · 2025-03-27 · 1 site observation
RECRUITING
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)NCT06883305 · 2025-03-18 · 1 site observation
RECRUITING
Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil LevelsNCT06334575 · 2025-02-12 · 1 site observation
RECRUITING
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBCNCT06078384 · 2024-12-27 · 1 site observation
RECRUITING
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.NCT06382948 · 2024-12-05 · 1 site observation
RECRUITING
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT06417814 · 2024-10-04 · 1 site observation
RECRUITING
Depemokimab Asthma Imaging and Bronchoscopy Sub-StudyNCT06979323 · 2024-07-19 · 1 site observation
RECRUITING
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)NCT05485961 · 2024-04-27 · 1 site observation
RECRUITING
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · 2023-12-15 · 1 site observation
RECRUITING
DESTINY Breast Respond HER2-(Ultra)Low EuropeNCT05945732 · 2023-10-24 · 1 site observation
RECRUITING
Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)NCT06055504 · 2023-09-06 · 1 site observation
RECRUITING
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerNCT05982093 · 2023-02-03 · 1 site observation
RECRUITING
Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerNCT05306041 · 2023-01-02 · 1 site observation
RECRUITING
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsNCT05232916 · 2022-12-16 · 1 site observation
RECRUITING
sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.NCT04766866 · 2021-03-02 · 1 site observation
RECRUITING
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy ProductsNCT00271180 · 1983-01-01 · 1 site observation
RECRUITING
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain MetsNCT07234877 · 2026-11-01 · 1 site observation
NOT_YET_RECRUITING
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIVNCT07053384 · 2025-07-10 · 2 site observations
ACTIVE_NOT_RECRUITING
A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical PracticeNCT07055607 · 2025-05-01 · 1 site observation
ENROLLING_BY_INVITATION
OptimAIR: Towards Right Care in Asthma Through Point-of-care Phenotyping, Guideline-based Assessment and Management Optimalisation Using the AsthmaOptimiser in Primary CareNCT07390669 · 2025-05-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)NCT06687369 · 2024-12-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1NCT06694805 · 2024-12-02 · 1 site observation
ACTIVE_NOT_RECRUITING
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of ExacerbationsNCT06529419 · 2024-08-30 · 1 site observation
COMPLETED
Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With AsthmaNCT06435273 · 2024-08-05 · 1 site observation
COMPLETED
Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain.NCT06321731 · 2024-07-02 · 1 site observation
COMPLETED
Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental DopplerNCT05284474 · 2024-06-03 · 2 site observations
NOT_YET_RECRUITING
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.NCT06372145 · 2024-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyNCT05979311 · 2024-02-21 · 2 site observations
ACTIVE_NOT_RECRUITING
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerNCT05896566 · 2024-01-23 · 1 site observation
COMPLETED
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)NCT05934526 · 2023-12-28 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.